Skip to main content

Table 2 Toxicities and side effects of concurrent radiotherapy for locally advanced rectal cancer

From: Prospective clinical study of capecitabine plus oxaliplatin concurrent chemoradiotherapy after radical resection of rectal cancer

Toxic reaction Grade 1–2 P Grade 3 P
CAPE-OX-CRT group (%) Control group (%) CAPE-OX-CRT group (%) Control group (%)
Diarrhea 14/30 (46.67%) 5/26 (19.23%) 0.028 5/30 (16.67%) 5/26 (19.23%) 0.431
Radiation dermatitis 15/30 (50%) 12/26 (46.15%) 0.774 3/30 (10%) 12/26 (46.15%) 1.000
Bone-marrow suppression 23/30 (76.67%) 10/26 (38.46%) 0.003 3/30 (10%) 10/26 (38.46%) 0.693
Nausea or vomiting 18/30 (60%) 7/26 (26.92%) 0.012 1/30 (3.85%) 7/26 (26.92%) 1.000
Liver dysfunction 9/30 (30%) 2/26 (7.70%) 0.047 0 2/26 (7.70%)
Peripheral neurotoxic reactions 6/30 (20%) 1/26 (3.85%) 0.108 0 1/26 (3.85%)
Hand-foot syndrome 1/30 (3.85%) 0 1.000 1/30 (3.85%) 0 1.000
Fatigue 14/30 (46.67%) 5/26 (19.23%) 0.028 0 5/26 (19.23%)